|
|
|
|
Non-adherence is the most important risk factor for
ledipasvir/sofosbuvir HCV treatment failure in the real world
|
|
|
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Dost Sarpel, Isaac Wasserman, Alyssa Trochtenberg, Kian Bichoupan, David DelBello, Ponni V Perumalswami, Alyson Harty, Daniel Fierer, Michael Mullen, Douglas Dieterich, Andrea D. Branch
Icahn School of Medicine at Mount Sinai, New York, NY, United States
|
|
|
|
|
|
|